Increasing evidence on the impact of the different wavelengths of sunlight on the skin
demonstrates the need for tailored recommendations of sunscreen according to skin …

abstract Interleukin (IL)-4 and IL-13, signature type 2 cytokines, exert their actions by binding
to two types of receptors sharing the IL-4R a chain (IL-4Ra). Since IL-4 and IL-13 play …

Background Nemolizumab is a subcutaneously administered humanized monoclonal
antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in …

Summary Background Interleukin (IL)‐31 affects the inflammatory response, is involved in
epidermal barrier disruption in atopic dermatitis (AD) and plays a key role in pruritus …

This is the English version of the Clinical Practice Guidelines for the Management of Atopic
Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with …

Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease, associated with
impaired skin barrier function and an atopic background. Various complicating factors, such …

Background Delgocitinib 0.5% ointment, a topical Janus kinase inhibitor, has been
approved in Japan for adult patients with atopic dermatitis (AD). Objective To evaluate the …

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and
significantly impacts patients' lives, particularly in its severe forms. AD clinical presentation …

Background Atopic dermatitis (AD) is the most common allergic disease in the world. While
genetic components play critical roles in its pathophysiology, a large proportion of its genetic …

Atopic dermatitis (AD) in older adults (elderly AD) has recently emerged as a newly defined
subgroup of AD. When selecting treatment options, clinical characteristics of elderly AD and …